Inicio › Leucemia linfocítica crónica › Maryland
Ensayos clínicos de Leucemia linfocítica crónica en Maryland
23 estudios sobre Leucemia linfocítica crónica buscan participantes en Maryland.
Ciudades en Maryland
Texto oficial del estudio (inglés)
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- National Institutes of Health Clinical Center, Bethesda
ReclutandoEstudio observacional
Edades de 18 a 110 · Todos los sexos · Actualizado el 12 nov 2026 · NCT00923507A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 111, Bethesda
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT05645107Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
- National Institutes of Health Clinical Center, Bethesda
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT01087333Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04269902A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- American Oncology Partners of Maryland Pa, Bethesda
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06846671ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- The Center for Cancer and Blood Disorders-Bethesda, Bethesda
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07342478Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
- National Institutes of Health Clinical Center, Bethesda
ReclutandoFase 1 temprana
Edades de 18 a 100 · Todos los sexos · Actualizado el 12 nov 2026 · NCT07428707A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Center for Cancer and Blood Disorders ( Site 5439), Bethesda
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT05947851A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- American Oncology Partners, PA, Bethesda
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06588478Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- y 10 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Maryland Oncology Hematology, Silver Spring
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07221500Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
- National Institutes of Health Clinical Center, Bethesda
ReclutandoEstudio observacional
Edades de 18 a 110 · Todos los sexos · Actualizado el 29 oct 2026 · NCT05724121A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT06943872Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
- National Institutes of Health Clinical Center, Bethesda
ReclutandoFase 1/2
Edades de 18 a 120 · Todos los sexos · Actualizado el 16 oct 2026 · NCT06364423Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT05006716Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- National Institutes of Health Clinical Center, Bethesda
ReclutandoFase 2
Edades de 18 a 85 · Todos los sexos · Actualizado el 24 sept 2026 · NCT03986034Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Maryland, Baltimore
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- American Oncology Partners of Maryland, PA, Bethesda
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05254743A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445, Bethesda
- Maryland Oncology Hematology - Silver Spring /ID# 267557, Silver Spring
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 mar 2026 · NCT04830137AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 dic 2025 · NCT05602363De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.